Open AccessEfficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation
Author(s) -
Francesco Dentali,
Nicoletta Riva,
Mark Crowther,
Alexander G.G. Turpie,
Gregory Y.H. Lip,
Walter Ageno
Publication year - 2012
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.112.115410
Subject(s) - medicine , atrial fibrillation , dabigatran , cardiology , intensive care medicine , warfarin
Novel oral anticoagulants (NOACs) have been proposed as alternatives to vitamin K antagonists for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Individually, NOACs were at least noninferior to vitamin K antagonists, but a clear superiority in overall and vascular mortality was not consistently proven.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom